$RYTM News

Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

William Blair Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating

JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $145

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Progress In Prader-Willi And Genetically Defined Obesity Therapies

HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $130

RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159

Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Receives Health Canada Approval Of IMCIVREE For Additional Indication Of Weight Management In Adult And Pediatric Patients 4 Years Of Age And Older With Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years

Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today

Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120

Rhythm Pharmaceuticals (RYTM) Stock Looks Overvalued Despite Its 7x Five Year Run

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Rhythm Pharmaceuticals Receives Marketing Authorization For IMCIVREE From Japan's Ministry Of Health To Treat Acquired Hypothalamic Obesity